Educational content only. The following article is based on published scientific research and is provided for informational purposes. It does not constitute medical advice, diagnosis, or a treatment recommendation. Individual responses to any therapy vary. All peptide protocols at Irvine Health are available only after a licensed physician video consultation and a written prescription.
Investigational therapy. Retatrutide is not FDA-approved as of April 2026. This article reviews published research on a developmental peptide. Retatrutide is not currently available outside of registered clinical trials and is not prescribed at Irvine Health.
The peptide therapy landscape changed substantially when single-receptor GLP-1 agonists like semaglutide were joined by dual-receptor agents like tirzepatide. The next frontier — already producing remarkable Phase 2 and Phase 3 data — is triple-hormone receptor agonism. Retatrutide (development code LY3437943) is the most advanced triple agonist in clinical development, simultaneously activating GLP-1, GIP, and glucagon receptors. Phase 2 trial data in NEJM (2023) and the December 2025 TRIUMPH-4 Phase 3 readout suggest weight reduction approaching the outcomes historically associated with bariatric surgery.
The Three-Receptor Mechanism
Each of the three receptors retatrutide activates contributes a different pharmacologic effect:
- GLP-1 receptor agonism: The same mechanism as semaglutide — appetite suppression, slowed gastric emptying, enhanced glucose-dependent insulin secretion, and central effects on hunger and reward.
- GIP receptor agonism: The mechanism added by tirzepatide. GIP appears to enhance the metabolic response to GLP-1 and improve adipose tissue sensitivity.
- Glucagon receptor agonism: The novel addition. Glucagon receptor activation increases energy expenditure (basal metabolic rate), promotes lipolysis (fat breakdown), and modulates hepatic glucose production. Combined with the appetite-suppressing GLP-1 component, this produces a dual approach: eating less and burning more.
Glucagon receptor agonism on its own would worsen glycemic control by increasing hepatic glucose output; combining it with GLP-1 agonism appears to balance this effect, allowing the metabolic benefits without the diabetic side effects.
Phase 2 Trial: Setting the Stage
The Phase 2 trial enrolled 338 adults with obesity or overweight without type 2 diabetes. At 24 weeks, retatrutide at the 12 mg weekly dose produced a mean body weight reduction of 17.5%; at 48 weeks, the reduction reached 24.2%. Adverse effects were primarily gastrointestinal, consistent with other incretin-based therapies. The trial established proof of concept for triple-receptor agonism in obesity.
TRIUMPH-4: The First Positive Phase 3 Readout
TRIUMPH-4 enrolled 445 adults with obesity or overweight plus knee osteoarthritis (excluding type 2 diabetes). At 68 weeks, retatrutide produced mean body weight reductions of 28.7% at 12 mg and 26.4% at 9 mg, compared to 2.1% with placebo. These reductions exceed those reported with tirzepatide in SURMOUNT trials and approach outcomes historically achievable only with bariatric surgery.
Beyond weight, the trial reported a 75.8% reduction in osteoarthritis pain, an approximately 20% reduction in LDL cholesterol, and a 72% reversal rate from prediabetes to normoglycemia in the affected subpopulation. These are remarkable secondary findings that suggest broad metabolic and inflammatory effects.
Tolerability
Discontinuation rates due to adverse events were 12.2% at the 9 mg dose and 18.2% at the 12 mg dose — higher than for tirzepatide in comparable trials, reflecting the more aggressive pharmacology. Adverse events were predominantly GI: nausea, diarrhea, constipation, vomiting, decreased appetite. Notably, dysesthesia (altered sensation) was also reported, an adverse effect not commonly seen with single or dual incretin agonists; this likely relates to the glucagon receptor component.
Where Retatrutide Sits in Development
Eli Lilly's Phase 3 program for retatrutide includes seven additional registered trials evaluating its use in obesity, type 2 diabetes, and metabolic comorbidities, with completion expected through 2026 and into 2027. FDA submission and potential approval would follow the integrated analysis of these trials.
Until approval, retatrutide is not available as a prescribed medication. Compounding pharmacies cannot legally compound an unapproved peptide, and any product marketed as "retatrutide" outside of clinical trials should be regarded with significant skepticism — purity, dose accuracy, and safety cannot be verified.
What This Means for Patients Today
Retatrutide represents a meaningful step forward in obesity pharmacology and is worth following — but it is not currently a treatment option outside of clinical trials. Patients interested in evidence-based weight management today have semaglutide and tirzepatide, both with substantial trial data and FDA approval. As retatrutide moves through Phase 3 and toward potential FDA review, the clinical landscape will continue to evolve.
Looking Ahead
If retatrutide receives FDA approval, key questions to watch will include: cardiovascular outcomes data, long-term safety profile (especially the glucagon-receptor-related adverse effects), insurance coverage, comparative efficacy in head-to-head trials with tirzepatide, and the place of triple agonism in routine obesity care.
What This Means at Irvine Health
We do not currently prescribe retatrutide because it is not FDA-approved and cannot be legally compounded. As the regulatory landscape evolves, our physicians monitor publication of Phase 3 data, FDA actions, and approval pathways. If and when retatrutide becomes available, our practice will evaluate its place in our protocols based on rigorous review of the totality of evidence — efficacy, safety, individual patient profiles, and long-term outcomes data.
References
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. DOI: 10.1056/NEJMoa2301972.
- Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs in successful Phase 3 trial. Press release, December 2025.
- Rosenstock J, et al. Retatrutide for the treatment of obesity in adults with type 2 diabetes. Phase 2 trial. Lancet. 2023;402(10401):529-544.
- ClinicalTrials.gov. NCT04881760 — A Study of LY3437943 in Participants Who Have Obesity or Are Overweight (TRIUMPH-1).